Loading
NASDAQHealthcareBiotechnology
Latest quote
$30.875
+$1.025 · +3.43%
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Regular session
$30.875
+$1.025 · +3.43%
Regular session · ET · Market data may be delayed.
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Day range
Current $30.875
52-week range
Current $30.875
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
38
Expensive
Sentiment
63
Bullish
Risk
41
Elevated Risk
Momentum
74
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Day range
Current $30.875
52-week range
Current $30.875
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cost of goods sold | — | — | — | 15K USD |
| Gross profit | — | — | — | −15K USD |
| Research and development | 94.79M USD | 60.94M USD | 28M USD | 9.12M USD |
| Selling, general, and administrative | 30.31M USD | 22.12M USD | 8.18M USD | 1.37M USD |
| Operating expenses | 125.1M USD | 83.06M USD | 36.18M USD | 10.35M USD |
| Interest income | 13.62M USD | 12.14M USD | 2.53M USD | — |
| Interest expense | — | — | — | 285K USD |
| Depreciation and amortization | 1.02M USD | 839K USD | 112K USD | 15K USD |
| Operating income | −125.1M USD | −83.06M USD | −36.18M USD | −10.37M USD |
| Net income | −111.48M USD | −78.31M USD | −34.79M USD | −10.65M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$67.00
117.00% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI48.02M0.00%2.3T USD0.03%$382.3+0.72%
iShares Russell 2000 ETFIWM24.09M0.03%77.7B USD0.19%$279.22+0.59%
Vanguard Extended Market ETFVXF16.2M0.02%95.4B USD0.05%$235.28+0.92%
Vanguard Russell 2000 ETFVTWO8.57M0.05%18B USD0.06%$112.78+0.61%
iShares Russell 2000 Growth ETFIWO7.9M0.06%14.04B USD0.24%$357.3+1.08%
iShares Biotechnology ETFIBB6.65M0.06%10.41B USD0.44%$206.06+2.78%
Dimensional - US Small Cap ETFDFAS6.23M0.02%33.8B USD0.31%$78.4641+0.47%
State Street SPDR S&P Pharmaceuticals ETFXPH5.82M1.28%453.39M USD0.35%$64.815+1.86%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASState Street SPDR S&P Pharmaceuticals ETFXPHAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
